Amplified ferroptosis and immunomodulation triggered by NIR-II photothermal-controllable CRISPR/Cas9 nanoplatform to treat osteosarcoma and prevent postsurgical implant-associated infections
Amplified ferroptosis leads to significant tumor reduction, enhancing overall treatment efficacy against osteosarcoma.
Immunomodulation observed via the CRISPR/Cas9 nanoplatform aids in infection prevention after surgical procedures.
Assessment using a photothermal therapy approach shows improved outcomes versus standard treatments and lowers infection rates.
Potential advancements in therapeutics could arise from optimizing the CRISPR/Cas9 nanoplatform for broader applications in oncology and infection control.